Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q3 FY25 results · Oct–Dec 2024
Alivus Life Sciences reported revenue from operations of ₹641.84 crore (up 12.1% from Q3 FY24) and net profit of ₹136.96 crore (up 15.3% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a standalone basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 641.84 | 572.80 | +12.1% | 506.88 | +26.6% |
| Other income | 10.46 | 1.69 | +518.3% | 8.53 | +22.5% |
| Total income | 652.30 | 574.50 | +13.5% | 515.41 | +26.6% |
| Profit before tax | 185.15 | 160.68 | +15.2% | 127.46 | +45.3% |
| Net profit for the period | 136.96 | 118.77 | +15.3% | 95.32 | +43.7% |
| EPS, basic (₹) | 11.18 | 9.69 | +15.4% | 7.78 | +43.7% |
| Net margin (%) | 21.3 | 20.7 | 18.8 |
Standalone
- Filed with BSE
- 23 Jan 2025, 17:51 IST
- Board meeting
- 23 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE